Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 628
- Registration Number
- NCT03952143
- Locations
- 🇨🇳
Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Cn-21, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Cn-21, China
🇨🇳Shanghai Putuo District Center Hospital, Shanghai, Cn-31, China
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 354
- Registration Number
- NCT03952130
- Locations
- 🇦🇷
Centro Médico Viamonte, Caba, Buenos Aires, Argentina
🇦🇷Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina
🇨🇳Dongguan people's hospital, Dongguan, Guangdong, China
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT03890003
- Locations
- 🇺🇸
Sansum Diabetes Research Institute, Santa Barbara, California, United States
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT03849612
- Locations
- 🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT03848767
- Locations
- 🇺🇸
Rainier Clinical Research Center, Renton, Washington, United States
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 471
- Registration Number
- NCT03830281
- Locations
- 🇺🇸
Marin Endocrine Associates, Greenbrae, California, United States
🇺🇸Diabetes and Endocrine Associates, La Mesa, California, United States
🇺🇸Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
A Study of LY900014 in a Medtronic Pump
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT03760640
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸International Diabetes Center, Saint Louis Park, Minnesota, United States
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
- Conditions
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT03743285
- Locations
- 🇺🇸
Rainier Clinical Research Center, Renton, Washington, United States
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 751
- Registration Number
- NCT03740919
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Children's Hospital Los Angeles - Dept of Endocrinology, Los Angeles, California, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 60
- Registration Number
- NCT03682640
- Locations
- 🇸🇪
The Queen Silvia Children's Hospital / Sahlgrenska University Hospital, Gothenburg, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.